Herbal granules aim to slow eye disease in major trial
NCT ID NCT07189169
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether QA108 granules, a traditional Chinese medicine, can reduce drusen (fatty deposits) in the eyes of people with intermediate age-related macular degeneration. 400 participants will take the granules or a placebo for 24 weeks. The study aims to see if the treatment can slow disease progression and preserve vision.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QA108 granules (herbal medicine)
- What this could lead to
- If successful, QA108 granules could offer a new treatment option to slow or reduce drusen buildup in intermediate age-related macular degeneration, potentially preserving vision.
- What could go wrong
- This is an early Phase 3 trial with 400 participants, so results may not confirm effectiveness. The herbal intervention may have limited impact or side effects, and the specific TCM diagnosis may limit generalizability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERMEDIATE AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.